PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of brheartjLink to Publisher's site
 
Br Heart J. 1980 September; 44(3): 352–356.
PMCID: PMC482410

Primary pulmonary hypertension: effects of nifedipine.

Abstract

The results of the medical treatment of primary pulmonary hypertension are usually very poor. A case of severe primary pulmonary hypertension in chronic heart failure was treated with the calcium antagonist nifedipine, a powerful vasodilator which acts directly on vascular smooth muscle. Nifedipine, administered in a dose of 20 mg sublingually, caused a pronounced fall in pulmonary and systemic vascular resistances (54 and 49%, respectively) and a rise in cardiac output (90.3%). Improvement was maintained over a three-month period. These data suggest that nifedipine can be used in the treatment of this condition.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.0M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Images in this article

Click on the image to see a larger version.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • MARSHALL RJ, HELMHOLZ HF, Jr, SHEPHERD JT. Effect of acetylcholine on pulmonary vascular resistance in a patient with idiopathic pulmonary hypertension. Circulation. 1959 Sep;20:391–395. [PubMed]
  • SAMET P, BERNSTEIN WH, WIDRICH J. Intracardiac infusion of acetylcholine in primary pulmonary hypertension. Am Heart J. 1960 Sep;60:433–439. [PubMed]
  • CHARMS BL. Primary pulmonary hypertension. Effect of unilateral pulmonary artery occlusion and infusion of acetylcholine. Am J Cardiol. 1961 Jul;8:94–99. [PubMed]
  • SAMET P, BERNSTEIN WH. LOSS OF REACTIVITY OF THE PULMONARY VASCULAR BED IN PRIMARY PULMONARY HYPERTENSION. Am Heart J. 1963 Aug;66:197–199. [PubMed]
  • Satyanarayana Rao BN, Moller JH, Edwards JE. Primary pulmonary hypertension in a child. Response to pharmacologic agents. Circulation. 1969 Oct;40(4):583–587. [PubMed]
  • DRESDALE DT, MICHTOM RJ, SCHULTZ M. Recent studies in primary pulmonary hypertension, including pharmacodynamic observations on pulmonary vascular resistance. Bull N Y Acad Med. 1954 Mar;30(3):195–207. [PubMed]
  • GARDINER JM. The effect of priscol in pulmonary hypertension. Australas Ann Med. 1954 Feb;3(1):59–63. [PubMed]
  • Daoud FS, Reeves JT, Kelly DB. Isoproterenol as a potential pulmonary vasodilator in primary pulmonary hypertension. Am J Cardiol. 1978 Nov;42(5):817–822. [PubMed]
  • Wang SW, Pohl JE, Rowlands DJ, Wade EG. Diazoxide in treatment of primary pulmonary hypertension. Br Heart J. 1978 May;40(5):572–574. [PMC free article] [PubMed]
  • Fleckenstein A. Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle. Annu Rev Pharmacol Toxicol. 1977;17:149–166. [PubMed]
  • Guazzi M, Olivari MT, Polese A, Fiorentini C, Magrini F, Moruzzi P. Nifedipine, a new antihypertensive with rapid action. Clin Pharmacol Ther. 1977 Nov;22(5 Pt 1):528–532. [PubMed]
  • McMurtry IF, Davidson AB, Reeves JT, Grover RF. Inhibition of hypoxic pulmonary vasoconstriction by calcium antagonists in isolated rat lungs. Circ Res. 1976 Feb;38(2):99–104. [PubMed]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group